Date: October 27, 2022
Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST)
Electron activated dissociation (EAD) offered by the ZenoTOF 7600 system is a powerful tool for comprehensive characterization of protein therapeutics. Compared to traditional low-energy ExD approaches, the Zeno trap-boosted EAD offers a faster scanning rate and higher sensitivity, making it amenable as a single injection platform method for routine biopharma characterization. Additionally, the ability to tune electron kinetic energy in EAD enables its application to challenging molecules such as singly charged species and sulfated peptides. The EAD platform method provides the following benefits over collision-based MS/MS approaches: 1) confident identification and accurate localization of labile modifications, such as phosphorylation, glycosylation, sulfation and glycation; 2) unambiguous differentiation of amino acid isomers; and 3) di-/tri-sulfide bond mapping. In this presentation, the advantages of EAD for complete characterization of protein therapeutics will be highlighted.
- Learn about the advantages of EAD over traditional low-energy ExD and collision-based MS/MS approaches for complete characterization of protein therapeutics
- Gain insights into the benefits of EAD for localization of labile modifications and differentiation of isomers
- Get to know how the Biologics Explorer software facilitates analysis of EAD data
Webinars will be available for unlimited on-demand viewing after live event.